Articles tagged with: Revlimid
News»

During a session at the International Myeloma Workshop (IMW) held in Japan last week, Dr. Keith Stewart from the Mayo Clinic summarized the latest findings from research related to the protein cereblon and its impact on certain myeloma treatments.
Dr. Stewart reported that low levels of cereblon are associated with lower response rates and reduced survival outcomes in multiple myeloma patients treated with the immunomodulatory agents Revlimid (lenalidomide), thalidomide (Thalomid), and Pomalyst (pomalidomide).
He explained that, with further investigation, these findings may eventually help physicians customize therapy …
News»

Initial results of an ongoing Phase 2 clinical trial show that Kyprolis in combination with Revlimid and low-dose dexamethasone may be effective and safe in high-risk smoldering multiple myeloma patients.
Specifically, the results show that all patients responded to the combination therapy, with 75 percent of patients achieving at least a near complete response.
Progression-free or overall survival results are not yet available, though, to indicate whether the combination therapy delays progression to myeloma or extends overall survival.
Dr. Ola Landgren from the U.S. National Cancer Institute and National Institutes of Health …
News»

Looking back at all that has happened in the world of multiple myeloma since January of 2012, it is hard not to be impressed by the many important developments that took place.
There is the obvious fact that, during that time, not one, but two new drugs to treat myeloma were approved by the U.S. Food and Drug Administration (FDA). Prior to 2012, the FDA had not approved a novel anti-myeloma therapy in over six years.
Yet 2012 was meaningful to the myeloma community for reasons beyond the activity at the FDA’s …
News»

The National Comprehensive Cancer Network (NCCN) recently released an updated version of its guidelines for the diagnosis and treatment of multiple myeloma.
The most notable change to the guidelines is the addition of Kyprolis (carfilzomib), in combination with Revlimid (lenalidomide) and dexamethasone (Decadron), as an alternative treatment option for newly diagnosed myeloma patients eligible for a stem cell transplant.
The guidelines also now list Pomalyst (pomalidomide), in combination with dexamethasone, as a preferred salvage treatment for myeloma.
NCCN guidelines are followed closely by physicians and by many U.S. health …
News»

Results from a Phase 1b clinical trial indicate that Kyprolis in combination with Revlimid and low-dose dexamethasone is effective and safe for relapsed multiple myeloma patients.
Moreover, at the higher doses of Kyprolis and Revlimid tested during the trial, a greater share of patients responded to treatment than was the case in a trial testing Revlimid, Velcade, and dexamethasone in a similar patient population.
In addition, noticeably fewer cases of peripheral neuropathy – that is, pain, tingling, or loss of sensation in the extremities – were observed in the current study in …
Opinion»

Perhaps the title of this column more appropriately should be "Life After CRD," since I've now completed 24 cycles of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone (Decadron), commonly referred to as CRD, as part of a clinical trial for newly diagnosed patients.
However, since dexamethasone seemed to be the predominate source of my side effects, and because I liked the play on words, I went with the title as shown.
So, I've completed the clinical trial, I've reached stringent complete response, and I've won the first …
News»

Results of a small Phase 2 study may lead to improved outcomes for newly diagnosed patients who are unable to achieve a deep response with a Revlimid- or thalidomide-based initial therapy.
The study indicates that follow-on treatment with a Velcade-based regimen can noticeably deepen responses in these patients.
“We were certainly pleased to see that we were able to confirm our hypothesis that offering Velcade-containing, non-cross-resistant combinations to patients whose response had stalled after [Revlimid- or thalidomide-] based therapy can improve the depth of response,” said the study’s lead investigator, Dr. Ruben …